期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

TRAIL对CIA小鼠脾细胞表达Th1/Th2细胞因子的影响 被引量：1

TRAIL modulates splenocyte Th1/Th2 cytokines profile of CIA mice
下载PDF
导出
摘要 目的观察肿瘤坏死因子相关凋亡诱导配体(TRAIL)对胶原诱导型关节炎(CIA)小鼠的治疗效果,探讨TRAIL治疗类风湿性关节炎(RA)的可能机制。方法牛Ⅱ型胶原蛋白加弗氏完全佐剂免疫DBA/1J小鼠建立CIA模型,采用重组腺相关病毒AAV-TRAIL关节腔内注射进行治疗。CBA和流式细胞术检测Th1/Th2细胞因子的分泌。结果 AAV-TRAIL可改善CIA小鼠的病情,减轻关节红肿。体外研究其机制发现Ⅱ型胶原可以增加Th1型细胞因子TNF-α、IFN-γ、IL-2和Th2型细胞因子IL-4、IL-5的分泌,其中Th1型细胞因子的增加更为明显。而TRAIL则可显著抑制Ⅱ型胶原引起的Th1型细胞因子的上调,而对Th2型细胞因子的分泌没有影响。结论 TRAIL对CIA小鼠的治疗作用可能和TRAIL抑制Th1型细胞因子分泌相关。 Objective To investigate the effect of TRAIL on CIA mice and possible mechanism. Methods CIA was induced in DBA/1J mice with bovine type Ⅱ collagen and Freund＇s adjuvant. AAV-TRAIL particles were in- jected intra-articularly into knee joints of the mice. Th1/Th2 cytokines were detected by CBA method. Results The intra-articular injection of AAV-TRAIL reduced the severity of joint swelling in CIA mice. C Ⅱ increased the release of Thl cytokines （TNF-α, IFN-γ/and IL-2） and Th2 cytokines （ IL-4 and IL-5 ）, especially of Thl cyto- kines. And TRAIL significantly inhibited Thl cytokines release of splenocytes from CIA mice, but did not influence Th2 cytokines release. Condusions TRAIL inhibits Thl cytokines release, which perhaps is involved in anti-arthritis effect of TRAIL.
作者 刁智娟 朱洁卿 史娟 郑德先
机构地区 中国医学科学院基础医学研究所北京协和医学院医学分子生物学国家重点实验室
出处 《基础医学与临床》 CSCD 北大核心 2011年第12期1330-1334,共5页 Basic and Clinical Medicine
基金 国家自然科学基金(30972699)
关键词 类风湿性关节炎 CIA小鼠 肿瘤坏死因子相关凋亡诱导配体 TH1细胞因子 TH2细胞因子 rheumatoid arthritis （RA） collagen-induced arthritis （CIA） mice TRAIL Thl cytokine Th2 cytokine
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献11

  • 1Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector ceils in rheumatoid arthritis [ J ]. Immunol Rev, 2010, 233:233 - 255.
  • 2Morel J, Audo R, Hahne M, et al. Tumor necrosis factor- related apoptosis-inducing ligand (TRAIL) induces rheu- matoid arthritis synovial fibroblast proliferation through mi- togen-activated protein kinases and phosphatidylinositol 3- kinase/Akt [ J]. J Biol Chem, 2005, 280:15709- 15718.
  • 3Audo R, Combe B, Coulet B, et al. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases [ J ]. Cell Death Differ, 2009,16 : 1227 - 1237.
  • 4Pundt N, Peters MA, Wunrau C, et al. Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL-and TRAIL- induced apoptosis is cell cycle-dependent [ J ]. Arthritis Res Ther, 2009, 11 :R16.
  • 5Yao Q, Seol DW, Mi Z, et al. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis [ J ]. Ar-thritis Res Ther, 2006, 8:R16.
  • 6史娟,张锦春,畅晓燕,刘士廉,刘彦信,郑德先.重组可溶性TRAIL的表达与生物学活性[J].中国生物工程杂志,2003,23(6):46-49. 被引量：16
  • 7Shi J, Zheng DX, Liu YX, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice [ J ]. Cancer Res, 2005, 65:1687 - 1692.
  • 8唐艳旻,张丽梅,杨世方,朱冰,崔俊生,贾慧.重组变构人TRAIL对非小细胞肺癌细胞的体外抑制作用[J].基础医学与临床,2005,25(6):512-516. 被引量：3
  • 9Song K, Chen Y, GSke R, et al. Tumor necrosis factor-re- lated apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression [ J ]. J Exp Med, 2000, 191: 1095-1104.
  • 10Boissier MC. Cell and cytokine imbalances in rheumatoid synovitis [ J ]. Joint Bone Spine, 2011,78 : 230 - 234.

二级参考文献13

  • 1Wiley SR, Schooley K, Smolak D, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995,3:673 - 682.
  • 2Pitti RM, Marsters SA, Ruppert, et al. Induction of apoptosis by Apo-2 ligand, a new member of the Tumor Necrosis Factor cytokine family. J Biol Chem, 1996,271(22):12687 - 12690.
  • 3Liu Yanxin, Zhu Xun, Ma Zhengyu, et al. Expression, purification of and biological activity of rsTRAIL in E. Coli. Chin Sci Bulletin, 1999,Vol 44(14) : 1306 - 1309.
  • 4Hymowitz SG, O' Connel MP, Uhsch MH, et al. A Uhique zincbinding site revealed by high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry, 2000,39: 633 - 640.
  • 5Frese S, Brunner T, Gugger M, et al. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease easpase-8 inhibitory protein [J].J Thorae Cardiovasc Stag, 2002, 123(1):168- 174.
  • 6Song JH, Song DK, Herlyn M, et al. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-β-converting enzyme-llke inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells [J]. Clinical cancer research, 2003,9 : 4255 - 4266.
  • 7Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand [J]. J Clin Invest,1999,104 : 155 - 162.
  • 8Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling,biology, and potential for cancer therapy [J]. Cytokine Growth Factor Rev, 2003, 14:337 - 348.
  • 9MacFarlane M. TRAIL-induced signaling and apoptosis [J].Toxicology Letters, 2003, 139:89 - 97.
  • 10Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety [J]. J Pharmacol Exp Ther,2001,299: 31 - 38.

共引文献17

同被引文献4

引证文献1

基础医学与临床
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部